Comment on: Conventional and biologic disease-modifying anti-rheumatic drugs for osteoarthritis: a meta-analysis of randomized controlled trials: Reply

Persson, Monica S.M.; Sarmanova, Aliya; Doherty, Michael; Zhang, Weiya

Abstract

MD reports a grant from AstraZeneca funding a non-drug PI-led study in Nottingham (Sons of Gout study) and honoraria for Advisory boards on osteoarthritis and gout for AstraZeneca, Grunenthal, Mallinckrodt, and Roche, outside the submitted work. WZ reports honoraria for Grunenthal and speaker fees for Bioiberica and Hisun, outside the submitted work. All other authors have declared no conflicts of interest.

Citation

Persson, M. S., Sarmanova, A., Doherty, M., & Zhang, W. (2018). Comment on: Conventional and biologic disease-modifying anti-rheumatic drugs for osteoarthritis: a meta-analysis of randomized controlled trials: Reply. Rheumatology, 57(11), 2060–2061. https://doi.org/10.1093/rheumatology/key269

• Journal Article Type: Commentary
• Acceptance Date: Jul 23, 2018
• Online Publication Date: Sep 10, 2018
• Publication Date: Nov 1, 2018
• Deposit Date: Aug 8, 2018
• Publicly Available Date: Sep 11, 2019
• Electronic ISSN: 1462-0332
• Publisher: Oxford University Press (OUP)
• Peer Reviewed: Peer Reviewed
• Volume: 57
• Issue: 11
• Pages: 2060–2061
• DOI: https://doi.org/10.1093/rheumatology/key269
• Public URL: https://nottingham-repository.worktribe.com/output/972735
• Publisher URL: https://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/key269/5094545?rss=1